Trial Profile
A Post-authorization, Non-interventional, Safety Study Study of Patients With Myelodysplastic Syndromes (MDS) Treated With Lenalidomide
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms PASS MDS del5q
- Sponsors Celgene Corporation
- 26 May 2022 Status changed from active, no longer recruiting to completed.
- 17 Apr 2019 Planned primary completion date changed from 31 Mar 2019 to 31 Mar 2022.
- 17 Apr 2019 Status changed from recruiting to active, no longer recruiting.